Shamburg News · 8-K filed Oct 6, 2026, 8:00 AM EDT

Telomir Pharmaceuticals Closes $5.6 Million Private Placement at $1.16 Per Share

TELO · Telomir Pharmaceuticals, Inc.

  • Financing
  • Material agreement
  • Reg FD disclosure
  • Materiality: medium

Telomir Pharmaceuticals, Inc. entered into a securities purchase agreement on October 5, 2026 and closed a private placement of 4,843,300 common shares at $1.16 per share, a 5% discount to the 10-day VWAP, for approximately $5.6 million in gross proceeds. Existing significant shareholder John Paul DeJoria invested an additional $1.0 million. Alexander Capital, L.P. acted as placement agent, receiving a cash fee of approximately $455,000 and warrants to purchase 387,464 shares at $1.16, and the Company agreed to file a resale registration statement within 30 days of closing. Proceeds are intended to support clinical development of Telomir-Zn and for working capital.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 3.02, 7.01, 9.01, accession 0001493152-26-045860.

Written from the filing by Shamburg Markets. Figures are as reported by the company.